Positive Phase 3 data of Sanofi’s Dupixant has the company submitting data to the FDA for a fourth approval for the medication. According to Sanofi’s CFO, Jean-Baptiste Chasseloup de Chatillon the company’s plan to build Big Pharma’s “strongest franchise in immunology” hinges on their lead product Dupixent.
Click here to read the entire article.